NCT01473381.

Trial name or title	Safety and Efficacy of Vilazodone in Major Depressive Disorder (NCT01473381).
Methods	Randomised, double‐blind study.
Participants	Patients aged 18‐70 years, with MDD (according to DSM‐IV criteria). The patient's current major depressive episode must be at least 8 weeks and no longer than 12 months in duration.
Interventions	Vilazodone Citalopram Placebo
Outcomes	Primary Outcome Measure: MADRS score at 10 Weeks.
Starting date	November 2011.
Contact information	Sandra Beaird, PhD 1‐800‐678‐1605 ext 66297, info@forestpharm.com
Notes

DSM‐IV: Diagnostic and Statistical Manual of Mental Disorders

MADRS: Montgomery and Asberg Depression Rating Scale 
 MMD: major depressive disorder 
 MRI: magnetic resonance imaging 
 QIDS‐SR: Quick Inventory of Depressive Symptomatology Self‐Report